Literature DB >> 8550222

Structural characteristics of peptidoglycan fragments required to prime mice for induction of anaphylactoid reactions by lipopolysaccharides.

H Takada1, Y Kawabata, S Kawata, S Kusumoto.   

Abstract

Structural characteristics of peptidoglycan fragments required to prime mice for the induction of anaphylactoid reactions by Salmonella abortusequi lipopolysaccharide were examined in endotoxin-resistant C3H/HeJ mice, with special focus on the disaccharide-pentapeptide [N-acetylglucosaminyl-beta(1-4)-N-acetylmuramyl-L-alanyl-D -isoglutaminyl-meso-2,6-diaminopimelyl (DAP)-D-alanyl-D -alanine] and its smaller partial derivatives. The bacterial and synthetic muramyl tripeptides (DAP- and lysine [Lys]-type, respectively) and synthetic muramyl dipeptide primed mice for induction of anaphylactoid reactions accompanied by death within 1 h. The disaccharide-tripeptide exhibited weaker activity, and the disaccharide-tetrapeptide and muramyl tetrapeptide exhibited marginal activity. In contrast, intact peptidoglycans of various bacteria and the disaccharide-pentapeptide lacked the priming activity, although they showed adjuvant activity similar to that of the above components.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550222      PMCID: PMC173816          DOI: 10.1128/iai.64.2.657-659.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Macrophages produce somnogenic and pyrogenic muramyl peptides during digestion of staphylococci.

Authors:  L Johannsen; J Wecke; F Obál; J M Krueger
Journal:  Am J Physiol       Date:  1991-01

Review 2.  Mechanisms of the lethal action of endotoxin and endotoxin hypersensitivity.

Authors:  C Galanos; M A Freudenberg; M Matsuura
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

3.  Bacteroides lipopolysaccharides (LPS) induce anaphylactoid and lethal reactions in LPS-responsive and -nonresponsive mice primed with muramyl dipeptide.

Authors:  H Takada; H Hirai; T Fujiwara; T Koga; T Ogawa; S Hamada
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

4.  Enhancement of endotoxic shock by N-acetylmuramyl-L-alanyl-(L-seryl)-D-isoglutamine (muramyl dipeptide).

Authors:  E E Ribi; J L Cantrell; K B Von Eschen; S M Schwartzman
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

5.  Structural requirements of muramylpeptides for induction of necrosis at sites primed with Mycobacterium tuberculosis in guinea pigs.

Authors:  S Nagao; H Takada; K Yagawa; H Kutsukake; T Shiba; S Kusumoto; S Kawata; A Hasegawa; M Kiso; I Azuma
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

6.  Mitogenic effects of bacterial cell walls, their fragments, and related synthetic compounds on thymocytes and splenocytes of guinea pigs.

Authors:  H Takada; M Tsujimoto; S Kotani; S Kusumoto; M Inage; T Shiba; S Nagao; I Yano; S Kawata; K Yokogawa
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

7.  Processing of Bacillus subtilis peptidoglycan by a mouse macrophage cell line.

Authors:  M W Vermeulen; G R Gray
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

8.  Activation of the human complement cascade by bacterial cell walls, peptidoglycans, water-soluble peptidoglycan components, and synthetic muramylpeptides--studies on active components and structural requirements.

Authors:  A Kawasaki; H Takada; S Kotani; S Inai; K Nagaki; M Matsumoto; K Yokogawa; S Kawata; S Kusumoto; T Shiba
Journal:  Microbiol Immunol       Date:  1987       Impact factor: 1.955

9.  Enhancement of endotoxin lethality and generation of anaphylactoid reactions by lipopolysaccharides in muramyl-dipeptide-treated mice.

Authors:  H Takada; C Galanos
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

10.  Studies on a new immunoactive peptide, FK-156. II. Fermentation, extraction and chemical and biological characterization.

Authors:  T Gotoh; K Nakahara; T Nishiura; M Hashimoto; T Kino; Y Kuroda; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1982-10       Impact factor: 2.649

View more
  4 in total

1.  Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy.

Authors:  Chikako Ogawa; Yuen-Joyce Liu; Koichi S Kobayashi
Journal:  Curr Bioact Compd       Date:  2011-09

Review 2.  Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond.

Authors:  Mohammad Salem; Jakob Benedict Seidelin; Gerhard Rogler; Ole Haagen Nielsen
Journal:  Cell Mol Life Sci       Date:  2012-12-29       Impact factor: 9.261

3.  Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture.

Authors:  S Yang; R Tamai; S Akashi; O Takeuchi; S Akira; S Sugawara; H Takada
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  Interaction of cationic peptides with lipoteichoic acid and gram-positive bacteria.

Authors:  M G Scott; M R Gold; R E Hancock
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.